Results 191 to 200 of about 94,343 (283)

Correction: Advances in the structures, mechanisms and targeting of molecular chaperones. [PDF]

open access: yesSignal Transduct Target Ther
Gu J   +8 more
europepmc   +1 more source

Xeno interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes. [PDF]

open access: yesSci Adv, 2023
Sun Y   +8 more
europepmc   +1 more source

Precision Chemistry for Protein Lysine Modification

open access: yesChemistry – A European Journal, EarlyView.
Selective modification of lysine residues is challenging due to their similar intrinsic reactivity. Inspired by enzymatic recognition, ligand‐guided electrophiles enable site‐selective labeling and functionalization, while ligand‐guided catalyses achieve regioselective installation of bio‐relevant post‐translational modifications.
Mayu Onoda, Motomu Kanai
wiley   +1 more source

Molecular chaperones at the host-virus interface: heat shock protein roles in HIV-1 and emerging insights for HIV-2 and dual infection. [PDF]

open access: yesFront Cell Infect Microbiol
Arthur SE   +8 more
europepmc   +1 more source

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90. [PDF]

open access: yesInt J Mol Sci, 2022
Alberti G   +9 more
europepmc   +1 more source

Expression, Purification, and Microscopy‐Based Assays for Engineered Recombinant Tyrosinated, Detyrosinated, and Δ2 Human Tubulin

open access: yesCytoskeleton, EarlyView.
ABSTRACT Microtubules are noncovalent polymers assembled from α/β tubulin dimers. Their structure, dynamics and interaction with effectors are regulated through the expression of diverse tubulin isotypes and chemically diverse posttranslational modifications, also known as the “tubulin code.” Understanding the biophysical correlates between tubulin ...
Jiayi Chen   +2 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy